In vivo enrichment of cytidine deaminase gene-modified hematopoietic cells by prolonged cytosine-arabinoside application
S Brennig, I Rattmann, N Lachmann, A Schambach… - Cytotherapy, 2012 - Elsevier
Background aims Drug-resistance genes have been explored as powerful in vivo selection
markers in hematopoietic cell gene therapy, and cytidine deaminase (CDD) represents a
particularly attractive candidate given the virtual absence of non-hematopoietic side-effects
after low/intermediate dose application of the associated drug cytosine-arabinoside (Ara-C).
Methods We investigated the in vivo selection potential of CDD overexpression and
prolonged low/intermediate-dose Ara-C application in a murine model. Furthermore, non …
markers in hematopoietic cell gene therapy, and cytidine deaminase (CDD) represents a
particularly attractive candidate given the virtual absence of non-hematopoietic side-effects
after low/intermediate dose application of the associated drug cytosine-arabinoside (Ara-C).
Methods We investigated the in vivo selection potential of CDD overexpression and
prolonged low/intermediate-dose Ara-C application in a murine model. Furthermore, non …